# Jazz Pharmaceuticals (JAZZ) — Earnings

JAZZ · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/jazz/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $5.71 |
| EPS estimate | $6.18 |
| EPS surprise | −7.53% |
| Revenue surprise | +8.42% |
| Revenue | $1.2B |
| Revenue estimate | $1.1B |
| Reported | Aug 3, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/b507b060-2361-5f23-01c1-c4e4a079059a.html) |

Jazz Pharmaceuticals reported Q2 2026 results on August 3, 2026. Earnings per share were $5.71, below the $6.18 estimate by 7.53%. Revenue was $1.2 billion, ahead of the $1.1 billion consensus. A year earlier, in Q2 2025, Jazz posted a loss of $8.25 per share on revenue of $1.0 billion, so the latest quarter marks a return to profit for that period.

The longer record is uneven. Annual EPS rose from $13.13 in 2022 to $18.32 in 2023 and $21.19 in 2024, then fell about 61% to $8.20 in 2025. That loss is the lowest quarter in the table; the only other loss was Q4 2022, at $0.07 per share. The first half of 2026 adds up to $12.05, compared with a net loss of $6.57 for the first half of 2025. Quarterly revenue grew from $813.7 million in Q1 2022 to $1.1–1.2 billion recently. Over the last 20 quarters, Jazz beat the EPS estimate 11 times and missed 9 times.

Jazz reported its third quarter between November 5 and November 9 in each of the past five years. That points to early November 2026 for the Q3 report. It will show whether profits stay near recent levels.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 3, 2026 | $6.18 | $5.71 | -7.53% | $1.1B | $1.2B |
| Q1 2026 | May 5, 2026 | $4.66 | $6.34 | 36.17% | $978.5M | $1.1B |
| Q4 2025 | Feb 24, 2026 | $6.52 | $6.64 | 1.88% | $1.2B | $1.2B |
| Q3 2025 | Nov 5, 2025 | $5.95 | $8.13 | 36.72% | $1.1B | $1.1B |
| Q2 2025 | Aug 5, 2025 | −$7.61 | −$8.25 | -8.47% | $1.0B | $1.0B |
| Q1 2025 | May 6, 2025 | $4.66 | $1.68 | -63.93% | $983.8M | $897.8M |
| Q4 2024 | Feb 25, 2025 | $5.86 | $6.60 | 12.60% | $1.1B | $1.1B |
| Q3 2024 | Nov 6, 2024 | $5.50 | $6.61 | 20.22% | $1.0B | $1.1B |
| Q2 2024 | Jul 31, 2024 | $4.92 | $5.30 | 7.68% | $1.0B | $1.0B |
| Q1 2024 | May 1, 2024 | $4.18 | $2.68 | -35.87% | $954.0M | $902.0M |
| Q4 2023 | Feb 28, 2024 | $5.18 | $5.02 | -3.18% | $1.0B | $1.0B |
| Q3 2023 | Nov 8, 2023 | $4.93 | $4.84 | -1.88% | $968.4M | $972.1M |
| Q2 2023 | Aug 9, 2023 | $4.45 | $4.51 | 1.45% | $942.0M | $957.3M |
| Q1 2023 | May 10, 2023 | $4.24 | $3.95 | -6.83% | $897.4M | $892.8M |
| Q4 2022 | Mar 1, 2023 | $0.88 | −$0.07 | -107.93% | $975.5M | $972.1M |
| Q3 2022 | Nov 9, 2022 | $4.66 | $5.17 | 10.93% | $940.0M | $940.7M |
| Q2 2022 | Aug 3, 2022 | $4.18 | $4.30 | 2.91% | $902.5M | $932.9M |
| Q1 2022 | May 4, 2022 | $3.84 | $3.73 | -2.86% | $852.4M | $813.7M |
| Q4 2021 | Mar 1, 2022 | $3.63 | $4.21 | 15.95% | $864.3M | $896.7M |
| Q3 2021 | Nov 9, 2021 | $3.32 | $4.20 | 26.56% | $832.0M | $838.1M |

## Frequently Asked Questions

### When did Jazz Pharmaceuticals (JAZZ) last report earnings?

Jazz Pharmaceuticals last reported on Aug 3, 2026, covering fiscal Q2 2026.

### Did JAZZ beat earnings estimates?

No. Jazz Pharmaceuticals reported EPS of $5.71 for Q2 2026 against a $6.18 estimate — a 7.53% miss.

### How much revenue did JAZZ report last quarter?

Jazz Pharmaceuticals reported $1.2B in revenue for Q2 2026, against a consensus estimate of $1.1B.

## Similar Stocks

- [AXSM](https://www.lighthorse.io/tickers/axsm) — Axsome Therapeutics, Inc. - Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).